Security
INM · InMed Pharmaceuticals Inc.
INMNASDAQCommon stockCurrentCIK 1728328Updated Sep 29, 2026
INM price & chart
Loading TradingView…
NASDAQ:INM on TradingView ↗About the company
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. For more information, visit www.inmedpharma.com.
In the news
Recent filings
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other Events
Items 3.01, 8.01, 9.01
S-4/A filing
425 filing
10-K filing
SCHEDULE 13G filing
Show 5 more recent filings
425 filing
425 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
425 filing
425 filing
Financials
FY 2026 · USDSource
Source
Source
balance sheet · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 3,030,067Source | 15,580,040Source | 11,822,782Source | 14,106,340Source |
| Property, Plant and Equipment, NetUSD | 221,037Source | 992,199Source | 1,249,999Source | 723,426Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | 1,620,562Source | 1,783,198Source | 1,946,279Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 11,075,871Source | 6,571,610Source | 8,912,517Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 465,104Source | 352,838Source | 260,399Source |
| Inventory, NetUSD | — | 961,173Source | 1,244,324Source | 1,616,356Source |
| Assets, CurrentUSD | 2,676,706Source | 12,867,279Source | 8,689,585Source | 11,331,727Source |
| Prepaid Expense and Other Assets, CurrentUSD | 241,296Source | 321,747Source | 477,749Source | 498,033Source |
| Other Assets, NoncurrentUSD | 132,324Source | 100,000Source | 100,000Source | 104,908Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,955,060Source | 2,145,545Source | 2,616,673Source | 2,016,613Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 94,282,698Source | 91,221,174Source | 82,784,400Source | 77,620,252Source |
| Additional Paid in CapitalUSD | — | — | — | 35,741,115Source |
| Retained Earnings (Accumulated Deficit)USD | -130,230,406Source | -117,237,892Source | -109,075,759Source | -101,400,209Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 128,569Source | 128,569Source | 128,569Source | 128,569Source |
| Stockholders' Equity Attributable to ParentUSD | 1,075,007Source | 13,434,495Source | 9,206,109Source | 12,089,727Source |
| Additional Paid in Capital, Common StockUSD | 36,894,146Source | 39,322,644Source | 35,368,899Source | — |
| Liabilities and EquityUSD | 3,030,067Source | 15,580,040Source | 11,822,782Source | 14,106,340Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,955,060Source | 1,839,790Source | 1,971,808Source | 2,000,619Source |
| Operating Lease, Liability, CurrentUSD | — | 435,507Source | 317,797Source | 375,713Source |
| Accounts Payable, CurrentUSD | — | — | 41,004Source | — |
| Operating Lease, Liability, NoncurrentUSD | — | 305,755Source | 644,865Source | 15,994Source |
| Additional Financial Items | ||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | 1,952,363Source | — | 66,775Source |
| Accrued Liabilities, CurrentUSD | — | — | 256,473Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 2,200,000Source | 11,100,000Source | 6,600,000Source | — |
| Short-term InvestmentsUSD | 39,670Source | 43,384Source | 43,064Source | 44,422Source |
cash flow · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 7,900,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 205,271Source | 212,839Source | 219,600Source | 202,249Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 106,866Source | 119,307Source | 137,714Source | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | 114,690Source | 92,439Source | 219,147Source |
| Increase (Decrease) in InventoriesUSD | — | -283,151Source | -66,220Source | -565,561Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -8,643,513Source | -7,766,951Source | -6,985,832Source | -7,283,199Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | -9,293Source | -661,804Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | 1,790Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | 9,293Source | 160,014Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 94,496Source | 12,271,212Source | 4,654,218Source | 10,680,654Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | -2,340,907Source | 2,735,651Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 2,194,413Source | 11,075,871Source | 6,571,610Source | 8,912,517Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 106,866Source | 119,307Source | 137,714Source | 278,154Source |
| Amortization of Intangible AssetsUSD | 162,636Source | 162,636Source | 171,858Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 2,200,000Source | 11,100,000Source | 6,600,000Source | — |
| DepreciationUSD | — | 50,204Source | 47,742Source | — |
| Equipment ExpenseUSD | — | — | 700,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -58,009Source | -28,471Source | — | — |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | -7,151Source | — | -61,921Source | -48,175Source |
| Gain (Loss) on Disposition of AssetsUSD | -7,136Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -7,136Source | — | — | — |
| General and Administrative ExpenseUSD | 6,661,372Source | 6,557,822Source | 5,250,715Source | 5,847,518Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 1,457,926Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -11,373,141Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -1,187,709Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 7,100Source | 13,100Source |
| Inventory Write-downUSD | — | — | 305,812Source | 308,937Source |
| Investment Income, InterestUSD | 244,971Source | 155,882Source | 527,901Source | — |
| Net Income (Loss) Attributable to ParentUSD | -12,560,850Source | -8,162,133Source | -7,675,550Source | -7,947,622Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -12,992,514Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 527,901Source | — |
| Operating ExpensesUSD | 11,607,412Source | 9,653,052Source | 9,297,264Source | 9,781,823Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 431,165Source |
| Payments of Financing CostsUSD | — | — | — | 1,319,782Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 12,000,436Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | 1,365,755Source |
income statement · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total RevenueUSD | — | 4,942,633Source | 4,597,730Source | 4,135,561Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | — | — | — | -7,947,622Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 431,165Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -11,373,141Source | -8,162,133Source | -7,668,450Source | -7,934,522Source |
| Income Tax Expense (Benefit)USD | — | — | 7,100Source | 13,100Source |
| Net Income (Loss) Attributable to ParentUSD | -12,560,850Source | -8,162,133Source | -7,675,550Source | -7,947,622Source |
| Earnings Per Share, BasicUSD per share | -3.12Source | -8.36Source | -1.01Source | -3.25Source |
| Earnings Per Share, DilutedUSD per share | -3.12Source | -8.36Source | -1.01Source | -3.25Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 4,163,598Source | 975,985Source | 7,621,075Source | 2,448,458Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 4,163,598Source | 975,985Source | 7,621,075Source | 2,448,458Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 162,636Source | 162,636Source | 171,858Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 205,271Source | 212,839Source | 219,600Source | 202,249Source |
| Equipment ExpenseUSD | — | — | 700,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -58,009Source | -28,471Source | — | — |
| General and Administrative ExpenseUSD | 6,661,372Source | 6,557,822Source | 5,250,715Source | 5,847,518Source |
| Gross ProfitUSD | — | 1,706,586Source | 1,100,913Source | 1,403,036Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -11,373,141Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -2.84Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -2.84Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -1,187,709Source | — | — | — |
| Interest Income, OtherUSD | — | — | — | 492,440Source |
| Investment Income, InterestUSD | 244,971Source | 155,882Source | 527,901Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -12,992,514Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 527,901Source | — |
| Operating ExpensesUSD | 11,607,412Source | 9,653,052Source | 9,297,264Source | 9,781,823Source |
| Other General and Administrative ExpenseUSD | — | — | — | 369,239Source |
| Research and Development ExpenseUSD | 3,028,473Source | 2,853,920Source | 3,765,028Source | 3,732,056Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | 1,365,755Source |
Offerings
Registration 333-297234
Filing attachments
ea030576901ex99-1.htm · 8-K · 2026-09-18
EX-99.1 2 ea030576901ex99-1.htm PRESS RELEASE Exhibit 99.1 Nasdaq: INM c/o Norton Rose Fulbright Canada LLP Suite 1800-510 West Georgia St. Vancouver, BC, Canada V6B 0M3 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Stockholders’ Equity Compliance Vancouver, BC - September 18, 2026 - InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pharmaceutical comp…
Read attachment ↗ea029864401ex99-1.htm · 8-K · 2026-07-22
EX-99.1 3 ea029864401ex99-1.htm PRESS RELEASE, ISSUED ON JULY 22, 2026 Exhibit 99.1 Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline WALTHAM, Mass., July 22, 2026 - Mentari Therapeutics, Inc. (“Mentari”), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 million private placement to leading healthcare investors. The proceeds from the private placement will enable the continued developmen…
Read attachment ↗ea029728401ex99-1.htm · 8-K · 2026-07-10
EX-99.1 3 ea029728401ex99-1.htm PRESS RELEASE, ISSUED ON JULY 6, 2026 Exhibit 99.1 InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4 Vancouver, British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) (“InMed” or the “Company”) today announced that it has entered into an amendment (the “Amendment”) to the previously announced definitive mer…
Read attachment ↗d131177dex420.htm · S-4 · 2026-07-02
EX-4.20 4 d131177dex420.htm EX-4.20 EX-4.20 Exhibit 4.20 Confidential Final Form THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PU…
Read attachment ↗d131177dex991.htm · S-4 · 2026-07-02
EX-99.1 14 d131177dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Consent to be Named as a Director InMed Pharmaceuticals Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto …
Read attachment ↗d131177dex992.htm · S-4 · 2026-07-02
EX-99.2 15 d131177dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Consent to be Named as a Director InMed Pharmaceuticals Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto …
Read attachment ↗